The Prevalence of Glaucomatous Risk Factors in Patients From a Managed Care Setting: A Pilot EvaluationByErvin N. Fang, MD,Simon K. Law, MD, PharmD,John G.Walt, MBA,Tina H. Chiang, PharmD, MBA,Erin N. Williams, RNFebruary 15th 2008
Disease Progression and the Need for Neuroprotection in Glaucoma ManagementByRohit Varma, MD,Patti Peeples, RPh, PhD,John G.Walt, MBA,Thomas J. Bramley, PhDFebruary 15th 2008
Current Management of Glaucoma and the Need for Complete TherapyByStuart J. McKinnon, MD, PhD,Lawrence D. Goldberg, MD,Patti Peeples, RPh, PhD,John G.Walt, MBA,Thomas J. Bramley, PhDFebruary 15th 2008
History of Neuroprotection and Rationale as a Therapy for GlaucomaByLeonard A. Levin, MD, PhD,Patti Peeples, RPh, PhDFebruary 15th 2008
Managed Care and the Impact of GlaucomaByClaiborne E. Reeder, RPh, PhD,Meg Franklin, PharmD, PhD,Thomas J. Bramley, PhDFebruary 15th 2008
